Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.
Martins-Branco D, Nader-Marta G, Molinelli C, Ameye L, Paesmans M, Ignatiadis M, Aftimos P, Salgado R, de Azambuja E. Martins-Branco D, et al. Among authors: de azambuja e. Eur J Cancer. 2023 Nov;194:113358. doi: 10.1016/j.ejca.2023.113358. Epub 2023 Sep 22. Eur J Cancer. 2023. PMID: 37857118
Current perspectives of epothilones in breast cancer.
Cardoso F, de Azambuja E, Lago LD. Cardoso F, et al. Among authors: de azambuja e. Eur J Cancer. 2008 Feb;44(3):341-52. doi: 10.1016/j.ejca.2007.11.019. Eur J Cancer. 2008. PMID: 18178426 Review.
Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
de Azambuja E, Paesmans M, Beauduin M, Vindevoghel A, Cornez N, Finet C, Ries F, Closon-Dejardin MT, Kerger J, Gobert P, Focan C, Tagnon A, Dolci S, Nogaret JM, di Leo A, Piccart-Gebhart MJ. de Azambuja E, et al. J Clin Oncol. 2009 Feb 10;27(5):720-5. doi: 10.1200/JCO.2008.17.2155. Epub 2008 Dec 22. J Clin Oncol. 2009. PMID: 19103732 Clinical Trial.
HER-2 as a target for breast cancer therapy.
Ignatiadis M, Desmedt C, Sotiriou C, de Azambuja E, Piccart M. Ignatiadis M, et al. Among authors: de azambuja e. Clin Cancer Res. 2009 Mar 15;15(6):1848-52. doi: 10.1158/1078-0432.CCR-08-1844. Clin Cancer Res. 2009. PMID: 19289395 Free article. No abstract available.
Multifactorial approach to predicting resistance to anthracyclines.
Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret JM, Qi Y, Symmans F, Pusztai L, D'Hondt V, Piccart-Gebhart M, Sotiriou C. Desmedt C, et al. Among authors: de azambuja e. J Clin Oncol. 2011 Apr 20;29(12):1578-86. doi: 10.1200/JCO.2010.31.2231. Epub 2011 Mar 21. J Clin Oncol. 2011. PMID: 21422418 Clinical Trial.
Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.
Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM, Ghenne C, Metzger-Filho O, Skrzypski M, Paesmans M, Ameye L, Piccart-Gebhart MJ, de Azambuja E. Saini KS, et al. Among authors: de azambuja e. Ann Oncol. 2012 Apr;23(4):853-9. doi: 10.1093/annonc/mdr352. Epub 2011 Aug 4. Ann Oncol. 2012. PMID: 21821551 Free article.
333 results